New gene therapy aims to stop sickle cell pain crises

NCT ID NCT07432867

Recruiting now Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Feb 28, 2026 · Last updated Jun 14, 2026 · Updated 12 times

Summary

This study tests a new gene therapy called DREAM01 for people with severe sickle cell disease who do not have a matching bone marrow donor. The therapy uses the patient's own blood stem cells, which are modified in a lab to produce healthy hemoglobin and reduce sickling. The goal is to reduce or eliminate painful blockages in blood vessels and prevent long-term organ damage. The trial is currently recruiting 15 participants aged 12 to 35.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Department of Biotherapy, Necker-Enfants Malades Hospital
RECRUITING

Paris, Île-de-France Region, 75015, France

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

SICKLE CELL DISEASE